Literature DB >> 3950467

Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis.

G R Owens, I L Paradis, S Gryzan, T A Medsger, W P Follansbee, H A Klein, J H Dauber.   

Abstract

Alveolar inflammation is thought to underlie the development of pulmonary fibrosis in several forms of diffuse lung disease including the connective tissue diseases. The relationship between inflammation and the clinical manifestations of systemic sclerosis (scleroderma), such as skin and lung involvement, is less clear. We therefore evaluated 14 never-smoking patients with systemic sclerosis with pulmonary involvement by bronchoalveolar lavage (BAL) and compared the results with those found in eight nonsmoking patients with idiopathic pulmonary fibrosis (IPF) and eight normal subjects. The patients with scleroderma also underwent gallium citrate Ga 67 scanning. We found that patients with scleroderma and pulmonary involvement have alveolitis that appears to wane with time. In addition, patients with systemic sclerosis have a cellular profile in lavage fluid that appears to differ from that of patients with IPF. Finally, we found a significant correlation between BAL cellular recovery and the single-breath carbon monoxide diffusing capacity in patients with systemic sclerosis but not in patients with IPF. We conclude that inflammation may play an important role in the pathogenesis of the pulmonary disease of scleroderma and that different mechanisms may lead to fibrosis in IPF and scleroderma.

Entities:  

Mesh:

Year:  1986        PMID: 3950467

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

1.  Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice.

Authors:  Masaki Fujita; Qing Ye; Hiroshi Ouchi; Eiji Harada; Ichiro Inoshima; Kazuyoshi Kuwano; Yoichi Nakanishi
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease.

Authors:  E Renzoni; P Rottoli; G Coviello; M G Perari; M Galeazzi; M Vagliasindi
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

Review 3.  Subclinical alveolitis in immunologic systemic disorders.

Authors:  B Wallaert
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.

Authors:  Diogo S Domiciano; Eloisa Bonfá; Claudia T L Borges; Ronaldo A Kairalla; Vera L Capelozzi; Edwin Parra; Romy Beatriz Christmann
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

5.  Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE).

Authors:  H Groen; M Aslander; H Bootsma; T W van der Mark; C G Kallenberg; D S Postma
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

6.  Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance.

Authors:  A Scheja; A Akesson; P Wollmer; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1993-10       Impact factor: 19.103

Review 7.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

8.  Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up.

Authors:  C Agustí; A Xaubet; J Roca; A G Agustí; R Rodriguez-Roisin
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

9.  Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases.

Authors:  B Wallaert; F Bart; C Aerts; A Ouaissi; P Y Hatron; A B Tonnel; C Voisin
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

10.  Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific.

Authors:  P Pantelidis; D S McGrath; A M Southcott; C M Black; R M du Bois
Journal:  Respir Res       Date:  2001-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.